Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188325 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT06188325 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 18 participants.
The verdict
NCT06188325, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate dose proportionality and pharmacokinetics for three different dose levels of eliglustat after single and repeated administration.
Interventions
- DRUG Eliglustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2018-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06188325
The ClinicalTrials.gov registry entry for NCT06188325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eliglustat is the first listed.
NCT06188325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06188325 about?
NCT06188325 is a clinical study titled "A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers". The primary objective of the study is to evaluate dose proportionality and pharmacokinetics for three different dose levels of eliglustat after single and repeated administration.
What is the current status of trial NCT06188325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-01-01. Estimated completion is 2018-03-26.
What interventions are being tested in trial NCT06188325?
The interventions under investigation include: Eliglustat (DRUG).
Who is sponsoring clinical trial NCT06188325?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.